Screener
Medtronic MDT Neuroscience — Depreciation
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Medtronic’s 10-K, filed June 18, 2026.
- Filed
- Jun 18, 2026, 4:27 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-044354
| (in millions) | Total Assets / April 24, 2026 | Total Assets / April 25, 2025 | Depreciation Expense / 2026 | Depreciation Expense / 2025 | Depreciation Expense / 2024 |
|---|---|---|---|---|---|
| Cardiovascular | $17,553 | $16,548 | $253 | $225 | $199 |
| Neuroscience | 18,514 | 18,476 | 320 | 282 | 252 |
| Medical Surgical | 32,535 | 33,317 | 225 | 205 | 194 |
| Total reportable segments | 68,602 | 68,340 | 798 | 711 | 645 |
| Other operating segments (1) | 4,827 | 4,433 | 127 | 113 | 94 |
| Corporate | 19,598 | 18,906 | 261 | 229 | 215 |
| Total | $93,028 | $91,680 | $1,186 | $1,054 | $954 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Medtronic's neuroscience — depreciation?
- Medtronic (MDT) reported neuroscience — depreciation of $85M in Q1 2026.
- How has Medtronic's neuroscience — depreciation changed year-over-year?
- Medtronic's neuroscience — depreciation increased by 18.1% year-over-year, from $72M to $85M.
- What is the long-term trend for Medtronic's neuroscience — depreciation?
- Over 4 years (2022 to 2026), Medtronic's neuroscience — depreciation has grown at a 4.9% compound annual growth rate (CAGR), from $265M to $321M.
- What does neuroscience — depreciation mean?
- This is the systematic allocation of the cost of tangible assets used by the Neuroscience segment over their useful lives. It reflects the wear and tear of manufacturing equipment and facilities used to produce medical devices.
Ask your AI about Medtronic's neuroscience — depreciation.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude